Trials / Withdrawn
WithdrawnNCT01697514
A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
A Phase 1 Trial of LY2940680 in Pediatric Patients With Recurrent or Refractory Rhabdomyosarcoma or Medulloblastoma
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 12 Months – 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find a recommended dose level of LY2940680 that can be safely given to children with medulloblastoma or rhabdomyosarcoma that has returned or doesn't respond to initial treatment. The study will also explore the changes in a cancer marker levels. Finally, the study will help document any antitumor activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2940680 | Capsule administered orally. |
| DRUG | LY2940680 | Powder administered orally (may be sprinkled on soft food). |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2016-07-01
- Completion
- 2016-07-01
- First posted
- 2012-10-02
- Last updated
- 2013-08-27
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01697514. Inclusion in this directory is not an endorsement.